| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/AJMG.1320190308 |
| P698 | PubMed publication ID | 6439041 |
| P2093 | author name string | DiLiberti JH | |
| Dennis NR | |||
| Farndon PA | |||
| Curry CJ | |||
| P433 | issue | 3 | |
| P304 | page(s) | 473-481 | |
| P577 | publication date | 1984-11-01 | |
| P1433 | published in | American Journal of Medical Genetics Part A | Q15755121 |
| P1476 | title | The fetal valproate syndrome. | |
| P478 | volume | 19 |
| Q24681122 | A clinical study of 57 children with fetal anticonvulsant syndromes |
| Q40739834 | A role for protein kinase C and its substrates in the action of valproic acid in the brain: implications for neural plasticity |
| Q57605633 | ACETAZOLAMIDE IN TREATMENT OF EPILEPSY |
| Q35902641 | Above genetics: lessons from cerebral development in autism |
| Q28345141 | Additional educational needs in children born to mothers with epilepsy |
| Q44157475 | An in ovo chicken model to study the systemic and localized teratogenic effects of valproic acid |
| Q36866412 | Animal models of autism: an epigenetic and environmental viewpoint |
| Q35095179 | Anti-epileptic drugs in pregnancy: current safety and other issues |
| Q39523329 | Anticonvulsants and brain development |
| Q39382554 | Are antiepileptic drugs harmful when taken during pregnancy? |
| Q48139327 | Associations between particular types of fetal malformation and antiepileptic drug exposure in utero |
| Q70346342 | Behavioral teratogenicity of valproic acid: selective effects on behavior after prenatal exposure to rats |
| Q26795404 | Bipolar disorder in women |
| Q35414137 | Brief report novel mechanism for valproate-induced teratogenicity. |
| Q51834824 | Clinical characteristics and management of bipolar disorder in women across the life span. |
| Q33581937 | Clinical teratology |
| Q36998336 | Cognitive/behavioral teratogenetic effects of antiepileptic drugs |
| Q24187306 | Common antiepileptic drugs in pregnancy in women with epilepsy |
| Q24246634 | Common antiepileptic drugs in pregnancy in women with epilepsy |
| Q39597543 | Congenital malformations associated with maternal use of valproic acid |
| Q28376388 | Contributions of dam and conceptus to differences in sensitivity to valproic acid among C57 black and SWV mice |
| Q40649469 | Course of psychiatric disorders in pregnancy. Dilemmas in pharmacologic management. |
| Q31012430 | Data from regulatory studies: What do they tell? What don't they tell? |
| Q38657897 | Deleterious effects of drugs on the developing nervous system. |
| Q48777564 | Developmental and behavioral effects of prenatal primidone exposure in the rat. |
| Q30498465 | Developmental neurotoxicity induced by therapeutic and illicit drugs |
| Q92030150 | Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability |
| Q37186130 | Do lamotrigine and levetiracetam solve the problem of using sodium valproate in women with epilepsy? |
| Q38550879 | Drug and environmental factors associated with adverse pregnancy outcomes. Part I: Antiepileptic drugs, contraceptives, smoking, and folate |
| Q41513746 | Drugs in pregnancy: anticonvulsants |
| Q37168123 | Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes |
| Q28298817 | Dysmorphology demystified |
| Q53923836 | Effect of valproate on zinc metabolism in fetal and maternal rats fed normal and zinc-deficient diets. |
| Q44945780 | Effect of valproic acid on fetal and maternal organs in the mouse: a morphological study |
| Q42717337 | Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome |
| Q37150340 | Epigenetic mechanisms in cerebral ischemia. |
| Q35048887 | Epilepsy and pregnancy: Report of an Epilepsy Research Foundation Workshop |
| Q88354851 | Exposure to Sodium Valproate during Pregnancy: Facial Features and Signs of Autism |
| Q78066093 | Facial anthropometric measurements in offspring of epileptic mothers |
| Q56093711 | Fetal Valproate Syndrome |
| Q52144366 | Fetal anticonvulsant exposure: effects on behavioral and physical development. |
| Q39289571 | Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid |
| Q28340841 | Fetal valproate phenotype is recognisable by mid pregnancy |
| Q33682465 | Fetal valproate syndrome |
| Q56266932 | Fetal valproate syndrome |
| Q48111766 | Fetal valproate syndrome: the Irish experience. |
| Q92483511 | Gene-environment interaction counterbalances social impairment in mouse models of autism |
| Q37537051 | Genetic differences in susceptibility to anticonvulsant drug-induced developmental defects |
| Q35106308 | IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study |
| Q30443028 | Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research |
| Q38593232 | In utero exposure to valproate increases the risk of isolated cleft palate. |
| Q42673085 | In vitro effects of folate derivatives on valproate-induced neural tube defects in mouse and rat embryos |
| Q28378312 | Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero |
| Q24680158 | Management of epilepsy in women |
| Q44915731 | Mapping a chromosomal locus for valproic acid-induced exencephaly in mice. |
| Q34193779 | Maternal issues affecting the fetus |
| Q46364985 | Metabolic disorders of embryogenesis |
| Q41929459 | Methylome repatterning in a mouse model of Maternal PKU Syndrome. |
| Q43866180 | Metopic craniosynostosis, probable effect of intrauterine exposure to maternal valproate treatment |
| Q30465721 | Mouse models of autism: testing hypotheses about molecular mechanisms |
| Q35289892 | Neonatal hypoglycaemia and withdrawal symptoms after exposure in utero to valproate |
| Q37980247 | Neurobehavioral consequences of prenatal antiepileptic drug exposure |
| Q37287941 | Neurological teratogenic effects of antiepileptic drugs during pregnancy |
| Q40741979 | New findings in fetal valproate syndrome: hiatal hernia, gastric volvulus and ectopic kidney |
| Q72257357 | Omphalocele in a newborn baby exposed to sodium valproate in utero |
| Q43977633 | Ophthalmic findings in fetal anticonvulsant syndrome(s). |
| Q44596408 | Patent ductus arteriosus in Fetal Valproate Syndrome |
| Q46607993 | Postmarketing surveillance for human teratogenicity: a model approach. |
| Q38625359 | Potential human developmental toxicants and the role of animal testing in their identification and characterization |
| Q51163016 | Pregnancy and epilepsy. |
| Q53577853 | Pregnancy and quality of life in women with epilepsy. |
| Q34761058 | Pregnancy outcome after in utero exposure to valproate : evidence of dose relationship in teratogenic effect |
| Q40585543 | Pregnancy, teratogenesis, and epilepsy. |
| Q44169564 | Preliminary results on pregnancy outcomes in women using lamotrigine |
| Q34098311 | Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. |
| Q70350332 | Prognosis in fetal valproate syndrome |
| Q36476778 | Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers |
| Q67271067 | Proximal phocomelia and radial ray aplasia in fetal valproic syndrome |
| Q35871433 | Reduced Adult Hippocampal Neurogenesis and Cognitive Impairments following Prenatal Treatment of the Antiepileptic Drug Valproic Acid |
| Q43795352 | Reduced corneal sensation and severe dry eyes in a child with fetal valproate syndrome |
| Q46592036 | Risk of hypospadias in newborn infants exposed to valproic acid during the first trimester of pregnancy: a case-control study in Spain |
| Q37713469 | Risk-benefit assessment of anticonvulsants in women of child-bearing potential |
| Q36379139 | Risks of pregnancy in women with epilepsy |
| Q63614944 | Serum antibodies to central nervous system antigens: An analysis of their relation with different human neurologic disorders |
| Q51509185 | Severe fetal valproate syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly. |
| Q54623033 | Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (delta 2(E)-valproate) in healthy male volunteers |
| Q69911174 | Sodium valproate, pregnancy, and infantile fatal liver failure |
| Q44353897 | Sp family of transcription factors is involved in valproic acid-induced expression of Galphai2. |
| Q37133573 | Syndromes, disorders and maternal risk factors associated with neural tube defects (I). |
| Q84581302 | Teratogenic effects of antiepileptic drugs |
| Q28332748 | Teratogenic effects of sodium valproate in the Jcl: ICR mouse fetus |
| Q37301544 | Teratogenicity and antiepileptic drugs: potential mechanisms |
| Q36082034 | Teratogenicity of sodium valproate |
| Q36760464 | Teratology in Pediatric Practice |
| Q35127991 | Teratology in the 20th century: environmental causes of congenital malformations in humans and how they were established |
| Q36923828 | The Effects of Pharmacological Agents on the Human Fetus |
| Q46257842 | The behavioral consequences of exposure to antiepileptic drugs in utero |
| Q24671544 | The longer term outcome of children born to mothers with epilepsy |
| Q41240632 | The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome |
| Q33930531 | The offspring of epileptic mother |
| Q35779335 | The pharmacology of bipolar disorder during pregnancy and breastfeeding |
| Q22252192 | The teratology of autism |
| Q34679552 | The transgenerational inheritance of autism-like phenotypes in mice exposed to valproic acid during pregnancy |
| Q41933966 | Toluene embryopathy |
| Q41725899 | Treating recurrent affective disorders during and after pregnancy. What can be taken safely? |
| Q34254779 | Treatment issues for women with epilepsy |
| Q34823805 | Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges |
| Q45383090 | Treatment options in juvenile myoclonic epilepsy |
| Q34123327 | Update on new developments in the study of human teratogens. |
| Q86427264 | Valproate fetopathy |
| Q43546464 | Valproate, but not lamotrigine, induces ovarian morphological changes in Wistar rats |
| Q37610273 | Valproate: a practical review of its uses in neurological and psychiatric disorders |
| Q37011415 | Valproic Acid-Induced Neural Tube Defects in Mouse and Human: Aspects of Chirality, Alternative Drug Development, Pharmacokinetics and Possible Mechanisms |
| Q38665970 | Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug |
| Q28366303 | Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells |
| Q36384705 | Valproic acid in epilepsy : pregnancy-related issues |
| Q28340641 | Valproic acid prenatal exposure. Association with lipomyelomeningocele |
| Q28362326 | Valproic acid therapy and neural tube defects |
| Q33922097 | Valproic acid use in psychiatry: issues in treating women of reproductive age. |
| Q52933504 | [EURAP: the European Registry of Antiepileptic Drugs and Pregnancy]. |
| Q52933135 | [Neuropsychological outcome following intrauterine exposure to valproate]. |
Search more.